How Mongiwa Hazel Ntuli bagged an actuarial science degree at 17
Mongiwa Hazel Ntuli began her university experience at 15.
She found herself having to adjust to the large age gaps between herself and her university peers.
Her family allowed her to have as normal a childhood as possible while encouraging her bright mind.
___________________________________________________________________________
While many at her age are still traversing through high school corridors, Mongiwa Hazel Ntuli has just bagged herself an actuarial science degree from the University of Pretoria at just 17 years old.
The young and bright mind from Rosettenville, Johannesburg, started her first year at university at 15, having accelerated through primary and high school.
How it all started
Mongiwa explains, 'When I was in Grade 3, I mistakenly wrote a Grade 4 mathematics paper and scored the highest of all the actual Grade 4 students. My teacher identified this and allowed me to write more Grade 4 papers and saw that I performed exceptionally well.'
Fast forward a few years and Mongiwa has pursued her passions in finance and mathematics, choosing actuarial sciences as a happy marriage of the two.
Her undergraduate experience
Mongiwa shares, 'Undergrad took up most of my time because I had to learn new study techniques because the ones I applied in high school were not sufficient anymore. I had a lot of help and a lot of tutors, which demanded a lot of my time. Spending so much time on my studies allowed me to learn to speak my mind more freely and to be more independent.'
READ MORE | Meet the founder of Distinguished Living, an interior design business
Undoubtedly, being the youngest in the lecture room is no easy feat and Mongiwa found herself having to find her place in the big world.
She explains, 'I can learn about other people easily and I can observe their behaviour effortlessly, while blending in with the students around me. Disadvantages were instances where I could not engage with other people because of a larger, more intimidating age gap. Once people learned about my age, they started treating me more like a younger sibling than treating me like another student.'
Mongiwa continues, 'I often felt out of place when attending big conferences or big events where serious topics are discussed and engagement was encouraged. There were highly intellectual people who I couldn't relate to or understand. They also didn't take into account that I only started learning about actuarial science relatively recently and didn't have an extensive background in that field.'
Off the cuff
What is the most important lesson you've learned from your journey so far? Never forget your roots but don't become your roots.
What are five fun things that you like to do in your free time? I love watching medical or murder mysteries series, reading financial and/or self-help books and playing tennis. I also love spending time with my younger brother. He has an interesting point of view on life. I also like listening to music.
If you could give advice to students aspiring to excel academically, what would it be? To never give up and to never stop learning. They should grab each and every opportunity they get and make sure that the decisions they make now don't come at the expense of the bright futures they could have.
What strategies or habits have been crucial to your success? Making sure I talk to my guardians/family and remain grounded. Praying is a huge part of my life and connecting with other people from other cultures helps me define myself more.
A strong support system
Although Mongiwa was encouraged to keep her age a secret so as to not be treated differently, through it all, her family as her support system gave a chance to experience a normal, loving and fulfilling childhood.
Mongiwa shares, 'I feel that my support system made it as normal as it could be. My age was not flaunted by my family members and I was protected by those around me. I never wanted to know another life.'
On her greatest source of support and inspiration, Mongiwa says, 'Definitely my aunt who taught me that failure is not final and to keep going no matter what comes my way. There will always be opposition or adversity whenever you are successful at something. I just have to learn to ignore it and take pride that I am doing the best I can.'
What's next for her?
Mongiwa has plans to pursue honours and masters degrees and dive into the world of work.
She explains, 'My short term goals are to actually pass my exams well enough to get an exemption and also have more job shadowing opportunities before I jump into anything long term. For the next few years I would love to have done something major for my guardians to show my appreciation, acquire some assets and have progressed in my academic and career life.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Those who invested in JSE (JSE:JSE) three years ago are up 59%
By buying an index fund, investors can approximate the average market return. But many of us dare to dream of bigger returns, and build a portfolio ourselves. For example, JSE Limited (JSE:JSE) shareholders have seen the share price rise 26% over three years, well in excess of the market return (20%, not including dividends). However, more recent returns haven't been as impressive as that, with the stock returning just 25% in the last year, including dividends. So let's investigate and see if the longer term performance of the company has been in line with the underlying business' progress. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. To paraphrase Benjamin Graham: Over the short term the market is a voting machine, but over the long term it's a weighing machine. By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time. JSE was able to grow its EPS at 8.9% per year over three years, sending the share price higher. We don't think it is entirely coincidental that the EPS growth is reasonably close to the 8% average annual increase in the share price. This suggests that sentiment and expectations have not changed drastically. Rather, the share price has approximately tracked EPS growth. The company's earnings per share (over time) is depicted in the image below (click to see the exact numbers). We know that JSE has improved its bottom line lately, but is it going to grow revenue? Check if analysts think JSE will grow revenue in the future. When looking at investment returns, it is important to consider the difference between total shareholder return (TSR) and share price return. The TSR incorporates the value of any spin-offs or discounted capital raisings, along with any dividends, based on the assumption that the dividends are reinvested. So for companies that pay a generous dividend, the TSR is often a lot higher than the share price return. As it happens, JSE's TSR for the last 3 years was 59%, which exceeds the share price return mentioned earlier. This is largely a result of its dividend payments! It's nice to see that JSE shareholders have received a total shareholder return of 25% over the last year. Of course, that includes the dividend. That gain is better than the annual TSR over five years, which is 8%. Therefore it seems like sentiment around the company has been positive lately. Someone with an optimistic perspective could view the recent improvement in TSR as indicating that the business itself is getting better with time. It's always interesting to track share price performance over the longer term. But to understand JSE better, we need to consider many other factors. To that end, you should be aware of the 1 warning sign we've spotted with JSE . But note: JSE may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast). Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on South African exchanges. — Investing narratives with Fair Values Vita Life Sciences Set for a 12.72% Revenue Growth While Tackling Operational Challenges By Robbo – Community Contributor Fair Value Estimated: A$2.42 · 0.1% Overvalued Vossloh rides a €500 billion wave to boost growth and earnings in the next decade By Chris1 – Community Contributor Fair Value Estimated: €78.41 · 0.1% Overvalued Intuitive Surgical Will Transform Healthcare with 12% Revenue Growth By Unike – Community Contributor Fair Value Estimated: $325.55 · 0.6% Undervalued View more featured narratives — Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Read This Before Considering Reunert Limited (JSE:RLO) For Its Upcoming R00.90 Dividend
Reunert Limited (JSE:RLO) is about to trade ex-dividend in the next 3 days. The ex-dividend date is usually set to be two business days before the record date, which is the cut-off date on which you must be present on the company's books as a shareholder in order to receive the dividend. The ex-dividend date is an important date to be aware of as any purchase of the stock made on or after this date might mean a late settlement that doesn't show on the record date. Thus, you can purchase Reunert's shares before the 25th of June in order to receive the dividend, which the company will pay on the 30th of June. The company's next dividend payment will be R00.90 per share. Last year, in total, the company distributed R3.66 to shareholders. Looking at the last 12 months of distributions, Reunert has a trailing yield of approximately 6.6% on its current stock price of R055.40. We love seeing companies pay a dividend, but it's also important to be sure that laying the golden eggs isn't going to kill our golden goose! That's why we should always check whether the dividend payments appear sustainable, and if the company is growing. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. Dividends are typically paid out of company income, so if a company pays out more than it earned, its dividend is usually at a higher risk of being cut. Reunert paid out 61% of its earnings to investors last year, a normal payout level for most businesses. That said, even highly profitable companies sometimes might not generate enough cash to pay the dividend, which is why we should always check if the dividend is covered by cash flow. Dividends consumed 70% of the company's free cash flow last year, which is within a normal range for most dividend-paying organisations. It's encouraging to see that the dividend is covered by both profit and cash flow. This generally suggests the dividend is sustainable, as long as earnings don't drop precipitously. Check out our latest analysis for Reunert Click here to see how much of its profit Reunert paid out over the last 12 months. Businesses with strong growth prospects usually make the best dividend payers, because it's easier to grow dividends when earnings per share are improving. Investors love dividends, so if earnings fall and the dividend is reduced, expect a stock to be sold off heavily at the same time. This is why it's a relief to see Reunert earnings per share are up 4.2% per annum over the last five years. Earnings per share growth has been slim, and the company is already paying out a majority of its earnings. While there is some room to both increase the payout ratio and reinvest in the business, generally the higher a payout ratio goes, the lower a company's prospects for future growth. The main way most investors will assess a company's dividend prospects is by checking the historical rate of dividend growth. Reunert's dividend payments are effectively flat on where they were 10 years ago. Should investors buy Reunert for the upcoming dividend? Earnings per share growth has been unremarkable, and while the company is paying out a majority of its earnings and cash flow in the form of dividends, the dividend payments don't appear excessive. To summarise, Reunert looks okay on this analysis, although it doesn't appear a stand-out opportunity. So if you want to do more digging on Reunert, you'll find it worthwhile knowing the risks that this stock faces. To help with this, we've discovered 1 warning sign for Reunert that you should be aware of before investing in their shares. A common investing mistake is buying the first interesting stock you see. Here you can find a full list of high-yield dividend stocks. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Those who invested in JSE (JSE:JSE) three years ago are up 59%
By buying an index fund, investors can approximate the average market return. But many of us dare to dream of bigger returns, and build a portfolio ourselves. For example, JSE Limited (JSE:JSE) shareholders have seen the share price rise 26% over three years, well in excess of the market return (20%, not including dividends). However, more recent returns haven't been as impressive as that, with the stock returning just 25% in the last year, including dividends. So let's investigate and see if the longer term performance of the company has been in line with the underlying business' progress. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. To paraphrase Benjamin Graham: Over the short term the market is a voting machine, but over the long term it's a weighing machine. By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time. JSE was able to grow its EPS at 8.9% per year over three years, sending the share price higher. We don't think it is entirely coincidental that the EPS growth is reasonably close to the 8% average annual increase in the share price. This suggests that sentiment and expectations have not changed drastically. Rather, the share price has approximately tracked EPS growth. The company's earnings per share (over time) is depicted in the image below (click to see the exact numbers). We know that JSE has improved its bottom line lately, but is it going to grow revenue? Check if analysts think JSE will grow revenue in the future. When looking at investment returns, it is important to consider the difference between total shareholder return (TSR) and share price return. The TSR incorporates the value of any spin-offs or discounted capital raisings, along with any dividends, based on the assumption that the dividends are reinvested. So for companies that pay a generous dividend, the TSR is often a lot higher than the share price return. As it happens, JSE's TSR for the last 3 years was 59%, which exceeds the share price return mentioned earlier. This is largely a result of its dividend payments! It's nice to see that JSE shareholders have received a total shareholder return of 25% over the last year. Of course, that includes the dividend. That gain is better than the annual TSR over five years, which is 8%. Therefore it seems like sentiment around the company has been positive lately. Someone with an optimistic perspective could view the recent improvement in TSR as indicating that the business itself is getting better with time. It's always interesting to track share price performance over the longer term. But to understand JSE better, we need to consider many other factors. To that end, you should be aware of the 1 warning sign we've spotted with JSE . But note: JSE may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast). Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on South African exchanges. — Investing narratives with Fair Values Vita Life Sciences Set for a 12.72% Revenue Growth While Tackling Operational Challenges By Robbo – Community Contributor Fair Value Estimated: A$2.42 · 0.1% Overvalued Vossloh rides a €500 billion wave to boost growth and earnings in the next decade By Chris1 – Community Contributor Fair Value Estimated: €78.41 · 0.1% Overvalued Intuitive Surgical Will Transform Healthcare with 12% Revenue Growth By Unike – Community Contributor Fair Value Estimated: $325.55 · 0.6% Undervalued View more featured narratives — Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
